AUPH
NasdaqGMAurinia Pharmaceuticals Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 22 recent filings. 11 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
Johnson Craig A Director | Grant / award | 23.93K | $0.00 | — | 2026-06-04 |
Goetz Kathleen Director | Grant / award | 23.93K | $0.00 | — | 2026-06-04 |
Nova Tina Susan Director | Grant / award | 23.93K | $0.00 | — | 2026-06-04 |
Bailey Jeffrey Allen Director | Grant / award | 23.93K | $0.00 | — | 2026-06-04 |
TANG KEVIN Director, Chief Executive Officer, 10% Owner | Buy (open market) | 2.3K | $15.35 | $35,289.65 | 2026-05-29 |
TANG KEVIN Director, Chief Executive Officer, 10% Owner | Buy (open market) | 262.68K | $15.31 | $4,021,661.42 | 2026-05-29 |
TANG KEVIN Director, Chief Executive Officer, 10% Owner | Buy (open market) | 343.52K | $15.28 | $5,249,000.88 | 2026-06-01 |
TANG KEVIN Director, Chief Executive Officer, 10% Owner | Buy (open market) | 99 | $15.34 | $1,518.66 | 2026-06-01 |
TANG KEVIN Director, Chief Executive Officer, 10% Owner | Buy (open market) | 206.01K | $15.28 | $3,147,756.40 | 2026-06-02 |
TANG KEVIN Director, Chief Executive Officer, 10% Owner | Code J | 10K | $1.65 | $16,500.00 | 2026-06-02 |
Robertson Stephen P. Chief Legal Officer | Grant / award | 115.54K | $0.00 | — | 2026-05-18 |
Hearne Michael S Chief Financial Officer | Grant / award | 116.14K | $0.00 | — | 2026-05-18 |
Hearne Michael S Chief Financial Officer | Grant / award | 70.23K | $0.00 | — | 2026-05-18 |
Cole Ryan Chief Operating Officer | Grant / award | 116.14K | $0.00 | — | 2026-05-18 |
Cole Ryan Chief Operating Officer | Grant / award | 70.23K | $0.00 | — | 2026-05-18 |
Keenan Greg SVP, Chief Medical Officer | Tax withholding | 8.07K | $14.32 | $115,548.08 | 2026-03-06 |
TANG KEVIN Director | Buy (open market) | 300K | $13.90 | $4,170,000.00 | 2026-02-27 |
TANG KEVIN Director | Buy (open market) | 214.84K | $14.12 | $3,033,526.68 | 2026-02-27 |
TANG KEVIN Director | Buy (open market) | 1.6K | $14.38 | $23,008.00 | 2026-02-27 |
TANG KEVIN Director | Buy (open market) | 83.56K | $14.33 | $1,197,429.13 | 2026-03-02 |
TANG KEVIN Director | Buy (open market) | 115.79K | $14.21 | $1,645,404.32 | 2026-03-02 |
TANG KEVIN Director | Buy (open market) | 184.21K | $14.22 | $2,619,437.76 | 2026-03-03 |
Source: SEC EDGAR Forms 4/4A (CIK 1600620). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
$AUPH shouda - couda -wouda the best day for some time to give anything that drives it to anywhere...🎈
$AUPH if tang was smart he would drop some news tmrw because the market is going to rip. But of course they won't say shit.
$AUPH I hope your network is truly in the “know”
@ScottyK13 my plan was to turn $AUPH to $TGTX before the big jump in price. I missed it.
$AUPH 16.50 close tomorrow. I know people who know people...
$AUPH Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is not just another risky biotech story. With Lupkynis, real revenue, growing profits, and 2026 guidance, this commercial-stage biotech stock deserves investor attention. https://biotechhealthx.com/biotech-news/could-aurinia-pharmaceuticals-auph-be-a-smart-long-term-buy-after-its-recent-struggles/
$AUPH never-ending tang isn't the answer
$AUPH Hot as crap outside and no breeze.... Man, I hate to be inside!
$AUPH We are due for some good news next week. I know, wishful thinking...
$AUPH Yup, today's action at close.
$AUPH SI 8.82M as of 5/29 litle less than the 9M before...
$AUPH This stock is a good summer extender. Cause it is gonna be a long one.
Latest news
Aurinia Pharmaceuticals and Four More Stocks See Activist Action
A Fresh Look At Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Consolidation
Health Care Roundup: Market Talk
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
Aurinia Pharmaceuticals CEO Buys $12.5 Million Worth of Shares
Aurinia Pharmaceuticals Insider Bought Shares Worth $12,455,227, According to a Recent SEC Filing
TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
We Believe Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings Are A Poor Guide For Its Profitability
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.